Treatment of Mild Alzheimer's Disease

First-Line Pharmacologic Treatment

The American College of Physicians recommends initiating a cholinesterase inhibitor, specifically donepezil 5 mg once daily, as first-line pharmacologic treatment for mild Alzheimer's disease, with consideration for dose escalation to 10 mg daily after 4-6 weeks if well-tolerated 1, 2
Donepezil is the preferred initial agent due to once-daily dosing, absence of hepatotoxicity, and favorable side effect profile compared to other cholinesterase inhibitors 1
The initial dose of donepezil should be 5 mg once daily for at least 4-6 weeks before considering a dose increase 1, 2
The dose of donepezil can be increased to 10 mg daily if the patient tolerates the initial dose well and greater efficacy is needed 1, 2

If donepezil is not tolerated or ineffective, consider switching to another agent, such as rivastigmine, which can be started at 1.5 mg twice daily and increased by 1.5 mg twice daily every 4 weeks as tolerated, with a maximum dose of 6 mg twice daily 1, 2
Galantamine can be started at 4 mg twice daily with meals and increased to 8 mg twice daily after 4 weeks, with a possible further increase to 12 mg twice daily based on benefit and tolerability 2

Cholinesterase inhibitors provide modest benefits, with a 5-15% improvement over placebo, and do not alter the underlying disease process 1
All patients with Alzheimer's disease, including those appropriately treated, continue to experience decline over time 3
The beneficial response to cholinesterase inhibitors may take 6-12 months to assess properly 1, 2

Vitamin E supplementation at a dose of 2000 IU daily can be considered as adjunct therapy to slow functional decline 1, 2
Essential non-pharmacologic strategies, such as establishing predictable daily routines, simplifying tasks, and using memory aids, should be implemented alongside medication 1
Controlling vascular risk factors and modifying lifestyle risk factors, such as smoking cessation, regular exercise, and a healthy diet, can also contribute to slowing cognitive decline 3

Cholinesterase inhibitors should be discontinued if side effects develop and do not resolve despite management strategies, or if there is poor medication adherence, continued deterioration at the pre-treatment rate after 6-12 months, or progression to severe or end-stage dementia 1, 2, 6

Major contraindications to cholinesterase inhibitors include uncontrolled asthma, angle-closure glaucoma, sick sinus syndrome, and left bundle-branch block 1, 6

Disease-modifying therapies under development may offer benefits beyond symptomatic treatment, particularly when initiated early in biomarker-confirmed Alzheimer's disease 1, 3
Timely diagnosis maximizes opportunities for intervention, clinical trial participation, and comprehensive care planning 3